Targeted HSPC Gene Integration via Alpha-Globin Locus Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies for β-thalassemia face challenges such as semi-random genomic integration leading to safety issues like tumor suppressor deactivation and immune rejection risks, and they do not adequately address the genetic cause or diminish α-globin levels, necessitating a safer and more effective approach for introducing therapeutic transgenes into hematopoietic stem and progenitor cells.
Innovation Solution
The method involves using a guide RNA that hybridizes specifically to either the HBA1 or HBA2 gene sequence, combined with an RNA-guided nuclease and a donor template, to achieve site-specific integration of a transgene, reducing off-target effects and ensuring the transgene is integrated into the correct locus, thereby correcting the β-globin imbalance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lentiviral vectors are used to deliver HBB transgene, then HBB protein levels are restored, but semi-random genomic integration causes safety issues like tumor suppressor deactivation and oncogene activation
Solution Approach 1:
The patent introduces a targetable sequence as an intermediary element at the integration site. This sequence serves as a recognition marker that enables site-specific integration through homology-directed repair, replacing the random integration mechanism of lentiviral vectors with a controlled, targeted process that avoids oncogene activation and tumor suppressor deactivation
Solution Approach 2:
The patent changes the integration mechanism from semi-random to site-specific by modifying the genomic target to include a targetable sequence. This parameter change in integration specificity transforms the safety profile of the gene therapy while maintaining transgene expression
2Reliability
If genome editing is used to upregulate fetal hemoglobin, then compensation for HBB loss is achieved, but the genetic cause is not addressed and α-globin imbalance persists
Solution Approach 1:
The patent extracts and removes the targetable sequence from its original location and inserts it specifically at the HBB locus. This extraction and repositioning enables precise targeting of the HBB gene for correction while simultaneously reducing α-globin levels by disrupting α-globin gene expression, thereby addressing both the HBB deficiency and the α-globin imbalance
Solution Approach 2:
The patent combines multiple therapeutic effects into a single intervention: HBB transgene delivery, α-globin level reduction, and genomic stabilization. By integrating the targetable sequence at the HBB locus, the therapy simultaneously addresses the primary HBB deficiency and the secondary α-globin imbalance that contributes to erythrotoxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the safe and effective integration of therapeutic transgenes, such as the HBB gene, into hematopoietic stem and progenitor cells, increasing adult hemoglobin levels and reducing α-globin levels, potentially curing β-thalassemia by ensuring targeted gene correction with reduced risks of off-target effects.
Implementation Method 1
a guide RNA that hybridizes specifically to either the HBA1 or HBA2 gene sequence
Data Source
AI summary
The present disclosure provides methods and compositions for genetically modifying hematopoietic stem and progenitor cells (HSPCs), in particular by replacing the HBA1 or HBA2 locus in the HSPCs with a transgene encoding a therapeutic protein.